Effects of acute and chronic fluoxetine treatment on CRH-induced anxiety

NeuroReport

Volumn 10, Issue 3, 1999, Pages 553-555

  To, C Thang ^a   Anheuer, Zsuzsanna E ^a   Bagdy, Gyorgy ^a  

^a NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

Author keywords

Anxiety; Corticotropin releasing hormone (CRH); Fluoxetine; Serotonin (5 HT); Social interaction test; SSRI antidepressant

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; FLUOXETINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; GROOMING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION;

EID: 0033601989     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199902250-00020     Document Type: Article

References (22)

1. 1. Sutton RE, Koob GF, Le Moal M et al. Nature 297, 331-333 (1982).
2. 2. Koob GF and Bloom FE. FASEB J 44, 259-263 (1985).
3. 3. Palkovits M, Brownstein MJ and Vale W. FASEB J 44, 215-220 (1985).
4. 4. Dunn A and File SE. Horm Behav 21, 193-202 (1987).
5. 5. Skutella T, Criswell H, Moy S et al. NeuroReport 5, 2181-2185 (1994)
6. 6. Heinrichs SC, Min H, Tamraz S et al. Psychoneuroendocrinology 22, 215-224 (1997)
7. 7. Skutella T, Probst JC, Renner U et al. Neuroscience 85, 795-805 (1998).
8. 8. Smith GW, Aubry JM, Dellu F et al. Neuron 20, 1093-1102 (1998).
9. 9. Den Boer JA, Westenberg HGM, Kamerbeek WDJ et al. Int Clin Psychopharmacol 2, 21-32 (1987).
10. 10. To CT and Bagdy G. Neuropharmacology 38, 279-282 (1999).
11. 11. Wiersma A, Baauw AD, Bohus B and Koolhaas JM. Psychoneuroendocrinology 20, 423-432 (1995)
12. 12. Handley SL, McBlane JW, Critcnley MAE and Njunge K. Behav Brain Res 58, 203-210 (1993).
13. 13. Gibbs DM and Vale W. Brain Res 280, 176-179 (1985)
14. 14. Bagdy G, Calogero AE, Murphy DL and Szemeredi K. Endocrinology 125, 2664-2669 (1989)
15. 15. Calogero AE, Bernardini R, Margioris AN el al. Peptides 10, 189-200 (1989).
16. 16. Li Q, Muma NA and Van de Kar LD. J Pharmacol Exp Ther 279, 1035-1042 (1996)
17. 17. Bagdy G and Makara GB. Eur J Pharmacol 275, 301-305 (1995).
18. 18. Bagdy G. Ann NY Acad Sci 851, 357-363 (1998)
19. 19. Banki CM, Karmacsi L, Bissette G and Nemeroff CB. Eur Neuropsychopharmacol 2, 107-113 (1992)
20. 20. Chrousos GP and Gold PW. JAMA 267, 1244-1252 (1992)
21. 21. Biro E, Sarnyai Z, Penke B et al. Neuroendocrinology 57, 340-345 (1993)
22. 22. Bourin M. Drug News Perspect 11, 342-349 (1998).